CN101711255A - 具有改变的电子传递途径的修饰珠蛋白 - Google Patents

具有改变的电子传递途径的修饰珠蛋白 Download PDF

Info

Publication number
CN101711255A
CN101711255A CN200880021531A CN200880021531A CN101711255A CN 101711255 A CN101711255 A CN 101711255A CN 200880021531 A CN200880021531 A CN 200880021531A CN 200880021531 A CN200880021531 A CN 200880021531A CN 101711255 A CN101711255 A CN 101711255A
Authority
CN
China
Prior art keywords
albumen
protein
hemoglobin
leu
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880021531A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托夫·埃里克·库珀
米歇尔·托马斯·威尔逊
布兰东·乔恩·里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Essex Enterprises Ltd
Original Assignee
University of Essex Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Essex Enterprises Ltd filed Critical University of Essex Enterprises Ltd
Publication of CN101711255A publication Critical patent/CN101711255A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880021531A 2007-06-29 2008-06-26 具有改变的电子传递途径的修饰珠蛋白 Pending CN101711255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0712685.7A GB0712685D0 (en) 2007-06-29 2007-06-29 Improvements relating to oxygen-carrying proteins (2)
GB0712685.7 2007-06-29
PCT/GB2008/002199 WO2009004309A1 (en) 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway

Publications (1)

Publication Number Publication Date
CN101711255A true CN101711255A (zh) 2010-05-19

Family

ID=38420974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880021531A Pending CN101711255A (zh) 2007-06-29 2008-06-26 具有改变的电子传递途径的修饰珠蛋白

Country Status (9)

Country Link
US (1) US8609814B2 (https=)
EP (1) EP2170948B1 (https=)
JP (1) JP2010531659A (https=)
CN (1) CN101711255A (https=)
AU (1) AU2008272721B2 (https=)
BR (1) BRPI0812403B8 (https=)
CA (1) CA2690370A1 (https=)
GB (1) GB0712685D0 (https=)
WO (1) WO2009004309A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6273261B2 (ja) 2012-04-30 2018-01-31 ダウ アグロサイエンシィズ エルエルシー 有害生物防除剤組成物送達ビヒクル
GB201704006D0 (en) * 2017-03-13 2017-04-26 Univ Essex Modified globin proteins
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5884323A (en) * 1995-10-13 1999-03-16 3Com Corporation Extendible method and apparatus for synchronizing files on two different computer systems
WO1997015591A1 (en) * 1995-10-23 1997-05-01 Rice University Hemoglobin mutants that reduce heme loss
GB0712683D0 (en) 2007-06-29 2007-08-08 Wivenhoe Technology Ltd Improvements relating to oxygen-carrying proteins(1)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIELS B.J. VOLLAARDA,ET AL: "A new sensitive assay reveals that hemoglobin is oxidatively modified in vivo", 《FREE RADICAL BIOLOGY & MEDICINE》 *
VE´RONIQUE BAUDIN-CREUZA,ET AL: "Additive Effects of b Chain Mutations in Low Oxygen Affinity Hemoglobin bF41Y,K66T", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
BRPI0812403B1 (pt) 2019-08-27
JP2010531659A (ja) 2010-09-30
US20100137189A1 (en) 2010-06-03
US8609814B2 (en) 2013-12-17
EP2170948B1 (en) 2016-11-02
CA2690370A1 (en) 2009-01-08
BRPI0812403A2 (pt) 2014-12-02
AU2008272721A1 (en) 2009-01-08
AU2008272721B2 (en) 2013-06-27
GB0712685D0 (en) 2007-08-08
WO2009004309A1 (en) 2009-01-08
EP2170948A1 (en) 2010-04-07
BRPI0812403B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
WO1991019505A1 (en) Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
US11124559B2 (en) Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
CN101711255A (zh) 具有改变的电子传递途径的修饰珠蛋白
US11298407B2 (en) Hemoglobin based oxygen carrier and method of preparation
US12180266B2 (en) Modified haemoglobin proteins
US5349054A (en) Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin
US6114505A (en) Hemoglobin mutants that reduce heme loss
AU2018390489B2 (en) Modified globin proteins
CA2366833C (en) Hemoglobin-antioxidant conjugates
WO2005041898A2 (en) Blood substitutes
US5334705A (en) Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
WO2009004310A1 (en) Modified globin proteins with attenuated electron transport pathway
Webster Development of" inside-out" PEGylated crosslinked hemoglobin polymers: Novel hemoglobin-based oxygen carriers (HBOC)
US6812207B1 (en) Hemoglobin mutants that reduce heme loss
Gu Engineering the Biophysical and Biochemical Properties of Polymerized Hemoglobin as a Red Blood Cell Substitute via Various Strategies
Arkosi et al. Selective polyethylene glycol attachment to hemerythrin for potential use in blood substitutes
Apperson Globin engineering studies: optimizing the designs of circularly permuted myoglobin and single-chain hemoglobin
AU715073C (en) Hemoglobin mutants that reduce heme loss
Fronticelli et al. Design, Conformational, Functional and Physiological Characterization of Recombinant Polymeric Heme-Proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Essex

Applicant after: University of Essex Industries Ltd

Address before: Essex

Applicant before: Wivenhoe Technology Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: WIVENHOE TECHNOLOGY LTD. TO: UNIVERSITY OF ESSEX INDUSTRY CO., LTD.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100519